ABSTRACT Many pathological conditions of the central nervous system involve damage to and removal of myelin membrane. Very little is known about initiation of this membrane damage and the mechanisms of disposal of the damaged tissue. We are interested in the interaction between complement (the components of complement are designated C1, C2, C3, etc.) and myelin membranes and the possible role of complement in amplifying myelin damage and in the disposal of damaged myelin in vivo, because activation of complement generates both membrane-attack complexes and opsonin(s). In this study, we found that isolated rat or human myelin consumes complement in the absence of specific antibodies. Activation of complement was demonstrated by showing C3 cleavage in fresh serum incubated with myelin. Incubation of central nervous system myelin with C2-deficient serum produced no C5 consumption and only minor factor B conversion, thus excluding the alternative pathway of activation. Involvement of the classical pathway was shown directly by the Cl fixation and transfer assay. Myelin incubated with C2-deficient serum or with purified CI and then washed contained Cl activity that could lyse sheep erythrocytes sensitized with anti-Forssman IgM antibody and carrying C4, together with C2 and C3-C9. Membranes in brain tissues other than myelin (heavy membrane fraction obtained on sucrose density gradient centrifugation) were unable to activate Cl.
Myelin membrane damage has been observed in various pathologic conditions of the central nervous system. This damage occurs in primary demyelinating diseases, such as multiple sclerosis, and as a consequence of extramyelin tissue damage in conditions such as infarct, trauma, and infection (1) (2) (3) (4) . There is much speculation on how myelin breakdown is initiated. Furthermore, it is not understood how the damaged myelin membranes and the myelin-associated proteins are disposed of. Breakdown products of myelin basic protein and its -fragments have been found in the cerebrospinal fluid (5) (6) (7) and in the systemic circulation (8) (9) (10) .
In this context, it is of interest to investigate the role of complement (the components of complement are designated C1, C2, C3, etc.) since its activation generates a membrane attack complex that could attack myelin. Membrane attack by complement is initiated when C5 is cleaved into C5a and C5b by C5 convertases generated by either classical or alternative pathway activation (11, 12) . When C5b binds to C6, a stable complex is formed that is capable ofcausing membrane damage together with C7, C8, and C9 (13) . Also, activation of complement generates nonspecific opsonins. 'Thus, in complement-mediated .phagocytosis, covalently bound C3b, a cleavage product of C3, on the membrane surface promotes efficient phagocytosis via C3b receptors on the phagocytic cell membrane (14, 15) .
Since the blood-brain barrier is -broken in most pathologic conditions in which extensive myelin loss occurs, central nervous system tissue is exposed to an abundance of complement. This raises the possibility ofits activation either with or without specific antibodies to brain tissue components. If so, complement might amplify the tissue damage. Also, complement could participate in the subsequent healing process. Accordingly, we have studied whether and how myelin itself could activate the complement system in the absence of myelin-specific antibodies.
MATERIALS AND METHODS
Buffers. Barbital-buffered saline (pH 7.4; g, 0.15) (Barb/ NaCl) was prepared by diluting a stock solution (16) Rapp and Borsos (21) with minor modification. Myelin was incubated with various amounts of human serum congenitally lacking C2 (C2-D) for 45 min at 370C and washed with G/Barb/NaCl. An equal volume of EAC4b,3b (1.0 X 108/ml) was added to this myelin suspension and the mixture was incubated at 30TC for 15 min. The suspension was then incubated with excess guinea pig C2 for 10 min at 300C. This was followed by incubation with a 1:40 dilution of guinea pig serum in EDTA/Barb/NaCl for 60 min at 370C. A similar experiment was performed with isolated human C1. In this case, the myelin suspension was incubated with human C1 instead of C2-D serum.
Immunoelectrophoresis. Crossed immunoelectrophoresis was carried out with anti-C3 in the second dimension according to Laurell (22) . RESULTS Inactivation of Complement by Myelin. Various amounts of rat central nervous system myelin were suspended in 0.2 ml of Barb/NaCl and incubated with 0.2 ml of a 1:50 dilution offresh normal human serum, as a source of complement, for 45 min at 370C in 1.5-ml Microfuge tubes to facilitate rapid pelleting of the myelin at the end of incubation. Portions (0.2 ml) of the supernates were assayed for residual complement by hemolytic tests with 0. 1 ml of EA (1.5 X 108/ml). As shown in Fig. 1 , residual complement activity diminished progressively as the amount of myelin increased. Similar results were obtained with human myelin.
Effect of Removing Possible Traces of Antimyelin Antibody from Normal Human Serum. For this purpose, undiluted normal human serum was treated with an equal volume of packed rat myelin for 15 min strictly at 0°C (to avoid complement activation) and then centrifuged to remove the myelin; this absorption treatment was repeated twice. The absorbed normal human serum and untreated normal human serum (control) were diluted 1:30 with G/Barb/NaCl and 0.2-ml portions of each were incubated for 45 min at 37°C with 0.2 ml of G/Barb/ NaCl containing 0.85 mg (wet weight) of rat central nervous system myelin. Then, the myelin was removed by centrifugation, and 0.2-ml portions of the supernates were assayed for residual C5 activity with EAC1,4b,2a,3b as described (23 To evaluate alternative pathway activation, 0.04-ml aliquots of normal human serum. or C2-D serum were incubated for 45 min at 370C with 3.4 mg (wet weight) ofrat central nervous system myelin. and analyzed by immunoelectrophoresis with a 1:2 dilution of anti-human factor B. Cleavage of factor B was detected by observing the conversion from a to y mobility. As positive controls, 0.04-ml portions of normal human and C2-D sera were incubated for 45 min at 370C with 40 j.g of zymosan washed with Barb/NaCl. As seen in Fig. 3 , complete conversion was produced by treatment of normal human serum with zymosan (pattern c in group A and patterns a and d in group B). In zymosan-treated C2-D serum, conversion was partial, presumably because only the alternative pathway was operative (pattern b in group A). Very little factor B conversion occurred when C2-D serum was incubated with myelin (pattern a in group A). It follows from these results that myelin activated the classical pathway. *Demonstration ofC3 Cleavage by Crossed Immunoelectrophoresis with Anti-Human C3. This experiment was carried out to show that classical pathway activation leads to generation of the C3 convertase C4b,2a and consequent C3 cleavage. Myelin was incubated with normal human serum for 45 min at 370C and the serum was analyzed by crossed immunoelectrophoresis. As shown in Fig. 4A , C3 conversion to C3b occurred when normal human serum was incubated with myelin. whereas incubation of normal human serum in the absence of myelin caused only slight conversion (Fig. 4B) C1 transfer assay. Ifactivated C1 is present on myelin previously incubated with C2-D serum, it can lyse EAC4b cells together with C2 and C3-C9 (21) . Fig. 5 shows that human myelin can activate C1 in C2-D serum. As would be expected, no C1 activity was observed on myelin that had been incubated with C2-D serum and then treated with EDTA/Barb/NaCl (results not shown). Direct C1 binding was also demonstrated by using purified C1. In this experiment, rat myelin suspensions were incubated with various amounts ofpurified human C1, washed, and then tested by the C1 transfer assay. As shown in Fig. 6 , the amount of hemolytically active C1 bound to myelin was linearly related.to the input ofpurified C1. Experiments with human central nervous system myelin gave identical results.
Comparison of Myelin Membrane and Heavy Membrane Fractions of Rat Brain for Ability to Activate Complement. To examine whether other membranes in the central nervous system can activate complement, the myelin and heavy membrane fractions obtained by sucrose gradient centrifugation ofrat brain were examined for capacity to activate complement by measuring C1 activation. We incubated various amounts of myelin or heavy membranes with different concentrations of C2-D serum. Membranes were washed and C1 activities on membranes were measured by C1 transfer assay as described above. Fig. 7 shows that membranes from the heavy membrane fraction did not carry significant C1 activity whereas myelin bound and activated C1 to an extent that was dependent on the amount of myelin and the input of C2-D serum as a source of C1.
DISCUSSION
Our results indicate that isolated human or rat central nervous system myelin activates the complement system. This was demonstrated indirectly in terms of decreased total hemolytic activity and loss of C5 in fresh normal serum. In the latter experiment, adsorption of normal human serum with rat myelin did not affect C5 consumption, which indicates that antimyelin antibody is not required. That loss of complement activity reflects complement activation was shown by detection ofC3 conversion to C3b during incubation of serum with myelin (Fig.  4) . Both rat and human central nervous system myelin activated guinea pig complement with an efficiency similar to that of human complement activation (results not shown). Involvement of the classical pathway is evident from the finding that complement consumption and significant factor B conversion did not occur when myelin was incubated with C2-D serum (Figs.  2 and 3 ).
Diverse substances other than antigen-antibody complexes, such as the lipid A component of lipopolysaccharide (24) , C-reactive protein complexes (25, 26) , and RNA viruses (27) , also activate complement by binding C1 through its Clq subunit. The binding of C1 triggers a series of intramolecular changes of subunits Cir and Cls, resulting in enzymatically active Cls whose substrates are C4 and C2 (28) (29) (30) .
In our experiments, involvement of C1 was demonstrated directly. Thus, C1 in C2-D serum was bound to myelin (Fig.  5) . Identical results were obtained when purified C1 devoid of antibodies was used instead ofC2-D serum (Fig. 6 ). In this case, the C1 molecules bound to myelin may include previously activated C1, since spontaneous activation of C1 can occur during purification (31) .
Previous studies with liposomes have shown that complement activation is not a general property of bilayer membranes (32, 33 were ineffective in activating C1 (Fig. 7) (20) . Since the blood-brain barrier is impaired in many pathologic lesions in which myelin membrane damage is observed, our demonstration of complement activation by myelin raises the possibility that tissue damage may be produced via membrane attack by C5b-9. Thus, it is conceivable that complement can amplify myelin damage after an initiating event. In turn, myelin membrane damage by complement may facilitate subsequent injury by other factors, such as proteolytic enzymes. In the absence ofdirect evidence, these concepts are speculative.
In addition, it is possible that complement may play a role in the healing process. Thus, the efficient disposal of central nervous system myelin followed by healing with gliosis has been observed in diseases that affect primarily myelin and those that affect brain tissue indiscriminately, such as infarct, trauma, and infection (1, 2) . Such brain damage is associated with extensive phagocytosis of myelin by astrocytes and macrophages and release of their breakdown products into the cerebrospinal fluid and systemic circulation (3) (4) (5) (6) (7) (8) . Effective phagocytosis can be mediated by the complement-derived opsonin system, thus enhancing proteolytic digestion ofmyelin by phagocytes. A similar role of complement involving C1 activation by C-reactive protein in the absence of antibody has also been suggested for removal of damaged tissue (25 
